Biosimilar
Merilog (Sanofi) — First Rapid-Acting Biosimilar
Who it is for
Patients prescribed Merilog (insulin aspart-szjj) by their doctor. Available to commercial/uninsured patients via Sanofi savings program. A new prescription is required to switch from another rapid-acting insulin — pharmacists cannot substitute Merilog automatically because it does not have FDA interchangeability status.
What it covers
First rapid-acting insulin biosimilar; ≤$35/month per Sanofi commitment; requires a new prescription from your doctor to switch (not pharmacist-substitutable like Semglee).
What it costs you
Sanofi published $35/month cost commitment, treated as a cost cap rather than a confirmed savings delta against a specific baseline price.
Products covered
NovoLog
Eligibility
- Patients prescribed Merilog (insulin aspart-szjj) by their doctor. Available to commercial/uninsured patients via Sanofi savings program. A new prescription is required to switch from another rapid-acting insulin — pharmacists cannot substitute Merilog automatically because it does not have FDA interchangeability status.
- Insurance status: uninsured, private, marketplace, medicare, medicaid, va, tricare
- Diabetes type: any
- Available in: all